Northland Capmk Lifts Earnings Estimates for Astera Labs

Astera Labs, Inc. (NASDAQ:ALAB) – Northland Capmk boosted their FY2025 earnings estimates for shares of Astera Labs in a report issued on Wednesday, November 5th. Northland Capmk analyst G. Richard now expects that the company will post earnings per share of $0.96 for the year, up from their previous estimate of $0.88. Northland Capmk has a “Hold” rating on the stock. The consensus estimate for Astera Labs’ current full-year earnings is $0.34 per share. Northland Capmk also issued estimates for Astera Labs’ Q4 2025 earnings at $0.30 EPS, Q1 2026 earnings at $0.24 EPS, Q2 2026 earnings at $0.26 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.22 EPS and FY2026 earnings at $0.95 EPS.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.10. The company had revenue of $230.58 million during the quarter, compared to analyst estimates of $206.42 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The business’s revenue for the quarter was up 103.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS.

A number of other equities research analysts also recently weighed in on the stock. Morgan Stanley upped their price target on shares of Astera Labs from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Needham & Company LLC boosted their target price on shares of Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday. Bank of America began coverage on Astera Labs in a report on Friday, October 3rd. They issued a “neutral” rating and a $230.00 target price on the stock. JPMorgan Chase & Co. upped their target price on Astera Labs from $180.00 to $215.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Citigroup raised their price objective on shares of Astera Labs from $160.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Thirteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.59.

Astera Labs Stock Performance

Shares of ALAB stock opened at $165.49 on Monday. The business’s fifty day moving average is $195.98 and its 200-day moving average is $141.10. Astera Labs has a 1 year low of $47.13 and a 1 year high of $262.90. The stock has a market cap of $27.95 billion, a PE ratio of 149.09, a price-to-earnings-growth ratio of 3.09 and a beta of 1.38.

Insider Buying and Selling at Astera Labs

In related news, Director Manuel Alba sold 183,000 shares of Astera Labs stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $173.27, for a total transaction of $31,708,410.00. Following the completion of the sale, the director owned 385,863 shares of the company’s stock, valued at approximately $66,858,482.01. This trade represents a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Truett Tate sold 18,861 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $183.51, for a total value of $3,461,182.11. Following the completion of the transaction, the chief financial officer owned 259,512 shares in the company, valued at $47,623,047.12. This trade represents a 6.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 534,480 shares of company stock valued at $97,000,380 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On Astera Labs

Several large investors have recently made changes to their positions in ALAB. Axxcess Wealth Management LLC increased its holdings in Astera Labs by 219.9% in the third quarter. Axxcess Wealth Management LLC now owns 13,590 shares of the company’s stock worth $2,661,000 after buying an additional 9,342 shares during the last quarter. Merit Financial Group LLC lifted its stake in Astera Labs by 3.1% in the third quarter. Merit Financial Group LLC now owns 5,683 shares of the company’s stock valued at $1,113,000 after acquiring an additional 170 shares during the last quarter. Vanguard Group Inc. grew its position in Astera Labs by 14.1% in the third quarter. Vanguard Group Inc. now owns 13,743,141 shares of the company’s stock worth $2,690,907,000 after acquiring an additional 1,693,918 shares in the last quarter. Tobam bought a new stake in Astera Labs in the third quarter worth approximately $1,126,000. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of Astera Labs by 7.2% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 46,516 shares of the company’s stock worth $9,108,000 after purchasing an additional 3,104 shares during the last quarter. Institutional investors own 60.47% of the company’s stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.